From anti-ageing to precision prevention

Longevity Medicine in 2025 is less a marketing term than a clinical work program: moving away from fuzzy “anti-aging” promises towards measurable risk, biomarker and intervention logic. Drivers are a consolidated biological framework of ageing, the rapid maturation of biomarkers of biological ageing (especially DNAm and multi-omics approaches) and growing evidence that certain interventions can improve hard clinical endpoints in older or high-risk populations (e.g. cardiovascular events under semaglutide in SELECT).